These proof of principle and mechanism studies demonstrate in a relevant lung cancer model a significant susceptibility of KRAS mutant/STK11 deficient lung adenocarcinoma to dual mTORC1/2 inhibition. This evidence concerns the gene KRAS and lung carcinoma.